With two weeks to go until The World's 50 Best Bars 2025, sponsored by Perrier, the bars ranked from No.51 to No.100 have been revealed for the ninth year. The annual list is created by votes from more than 800 independent experts, including bartenders, educators and drinks writers. — The 51-100 list includes bars spanning […]
The powerful combination of Aprecomm's CPE management and customer experience software, with VECTOR's expertise in network integration and operational support, offers broadband service providers a pathway to fully automated, self-healing networks. Today, VECTOR,a leading provider of managed services to telecommunications companies (telcos), and Aprecomm, the provider of an intuitive, self-healing network and customer experience platform,
With two weeks to go until The World's 50 Best Bars 2025, sponsored by Perrier, the bars ranked from No.51 to No.100 have been revealed for the ninth year. The annual list is created by votes from more than 800 independent experts, including bartenders, educators and drinks writers. — The 51-100 list includes bars spanning
Nokia and Boldyn Networks power the future of mining at Callio Pyhajarvi with private 5G network GlobeNewswire September 24, 2025 Press Release Nokia and Boldyn Networks power the future of mining at Callio Pyhajarvi with private 5G network Deployment enables safer, smarter, and more sustainable operations, where most workforces can operate from above ground. 24
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab (Leqembi) for the treatment of adult patients with mild cognitive impairment or mild dementia due to Alzheimer's disease (early Alzheimer's disease) that are apolipoprotein E4 (ApoE4) non-carriers or heterozygotes, with confirmed amyloid pathology. In response
— ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after breakthrough disease* on fingolimod or fumarate-based therapies1 — Following switch toKesimpta, over 90% of people with RMS showed no evidence of disease activity (NEDA-3) and low annualized relapse
(NasdaqGM:BNR),(LSE:BNR), TOKYO and GUANGZHOU, China, Sept. 24, 2025 (GLOBE NEWSWIRE) — Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech Limited (NASDAQ: BNR, “Burning Rock”) today announced that the OncoGuide(TM) OncoScreen(TM) Plus CDx System based on OncoScreen(TM) Plus to be used as a companion diagnostic for AstraZeneca's capivasertib has received Manufacturing and Marketing Approval
Burning Rock's OncoGuide(TM) OncoScreen(TM) Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer GlobeNewswire September 24, 2025 TOKYO and GUANGZHOU, China, Sept. 24, 2025 (GLOBE NEWSWIRE) — Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech Limited (NASDAQ: BNR, “Burning Rock”) today announced that the OncoGuide(TM) OncoScreen(TM)
ROAD TOWN, British Virgin Islands, Sept. 24, 2025 (GLOBE NEWSWIRE) — Lyno AI has already passed a major presale mark with investor interest increasing. The Early Bird stage has reported sales of 793,580 tokens at $0.050 each and a total of 39,679. The demand is still growing as the market anticipates the next step at
Lyno AI Officially Announces Presale Milestone as Investor Demand Accelerates GlobeNewswire September 24, 2025 ROAD TOWN, British Virgin Islands, Sept. 24, 2025 (GLOBE NEWSWIRE) — Lyno AI has already passed a major presale mark with investor interest increasing. The Early Bird stage has reported sales of 793,580 tokens at $0.050 each and a total of